The cervical cancer vaccine Gardasil could someday be approved for use in males. The vaccine is currently used for females aged 9 through 26 to protect them against the sexually transmitted Human Papillomavirus (HPV), which can ultimately lead to cervical cancer.
Drug maker Merck presented the Food and Drug Administration a study that found Gardasil prevented 90% percent of genital lesions in young men caused by HPV. They are asking that Gardasil be expanded for use in males of the same age group as females. However, it could take months for the FDA to make any type of decision.